Contact A Counsellor

counsellor button


teen suicide icon


panic anxiety icon

panic anxiety icon

#MindfulMondays with Miss SA

teen suicide icon


Research on Depression in the Workplace.

For more information please click here



email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here


Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 8 Issue1

Click here for more info


journalists crew making newspaper

If you are a journalist writing a story contact Kayla on 011 234 4837  media@anxiety.org.za


MySchool Facebook banner Nov

It’s the small things that make a BIG difference. Sign up for the “My School | My Village | My Planet” Card and start making a difference to Mental Health in South Africa today.

Click Here


cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

Antipsychotics may cause rapid weight gain in youth

Tue Oct 27, 2009 4:21pm EDT

[-] Text [+]

By Julie Steenhuysen

CHICAGO (Reuters) - Up to a third of children and adolescents who took common antipsychotic drugs for the first time became overweight or obese in as little as 11 weeks, raising their risk for diabetes and heart disease, U.S. researchers said on Tuesday.

They said doctors who prescribe antipsychotics to children should carefully consider the benefits against the risks.

"These data confirm prior findings that children and adolescents are highly vulnerable to antipsychotic medication," Dr. Christopher Varley and Dr. Jon McClellan of the Seattle Children's Hospital wrote in a commentary in the Journal of the American Medical Association.

"These results challenge the widespread use of atypical antipsychotic medications in youth," they wrote.

Dr. Monica Michell, a child psychiatrist at Lenox Hill Hospital in New York who was not involved with the study, said it "cautions us and underscores the long-term potential harm that these medicines can do."

"For children who are not psychotic or bipolar, these medicines should be a last resort," she said by email.

The study looked at four of the most common antipsychotic drugs used in children -- Johnson & Johnson's Risperdal or risperidone, Eli Lilly's Zyprexa or olanzapine, Bristol-Myers Squibb's Abilify or aripiprazole and AstraZeneca's Seroquel or quetiapine.

The researchers, led by Dr. Christoph Correll of Zucker Hillside Hospital and the Feinstein Institute for Medical Research in New York, studied 272 children and teens aged 4 to 19 with bipolar disorder, schizophrenia and disruptive or aggressive behavior spectrum disorders.

After roughly 11 weeks, those who took Zyprexa gained an average of 18.7 pounds (8.5 kg), those on Seroquel gained 13.4 pounds (6.1 kg), those on Risperdal gained 11.7 pounds (3.5 kg) and those on Abilify gained 9.7 pounds (4.4 kg).

Altogether, 10 percent to 36 percent of patients became overweight or obese within 11 weeks. Changes in cholesterol levels and other measures varied by drug, the team reported.

Only two atypical antipsychotics are already approved for youth -- Risperdal and Abilify. But in June, a Food and Drug Administration panel of experts backed wider use of Zyprexa, Seroquel and Pfizer's Geodon for children and teens.

At the time, many panel members expressed concern about rising sales of the drugs to young people and the lack of long-term safety studies.

They were especially worried about the chance the drugs might be misused to treat other conditions such as attention deficit hyperactivity disorder.

The FDA has yet to act on the panel's endorsement.

Last November, a panel of outside experts called on the FDA and other U.S. health agencies to study the long-term effects of prescribing antipsychotic drugs to children


Our Sponsors

Our Partners